Reuters
08 Jun 2026, 07:41 UTC · 6h ago
Zealand Pharma shares drop 20% as obesity drug side effects raise concerns
Top 1 mover · tap to explore
Reuters
08 Jun 2026, 07:41 UTC · 6h ago
Top 1 mover · tap to explore
Story key points
2 claims · impact-rated
Trial data for Zealand Pharma's obesity drug survodutide showed higher patient dropout rates and worse side effects compared to rival treatments. — Poor tolerability and dropout rates significantly reduce the drug's competitive viability in a high-growth market.
-0.80Zealand Pharma's shares fell more than 20% in early Monday trading. — The immediate price drop reflects a rapid repricing of the company's valuation based on the failed clinical expectations.
-0.40Ticker attribution
Model heads
Shares fell over 20% due to trial data showing worse side effects and higher dropout rates for its obesity drug.
Continue reading
6 related stories
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
6 dimensions · 9 clusters
Market reaction
0 bid · 10 offered
No stock impact ranking available yet.
WSJ
4h ago
